Published in Breast Cancer Weekly, April 8th, 2000
The findings contrast with those of uncontrolled studies in patients with high-risk primary breast cancer treated with high-dose chemotherapy and autologous hematopoietic stem cell support, indicated researchers.
G.N. Hortobagyi, University of Texas M.D. Anderson Cancer Center, and colleagues conducted a prospective randomized trial comparing standard-dose chemotherapy with the same therapy followed by high-dose chemotherapy in patients who, after primary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Breast Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.